Research programme: histone methyltransferase inhibitors - Celgene/EpizymeAlternative Names: CARM1 inhibitors; coactivator-associated arginine methyltransferase 1 inhibitors; EPZ 020411; HMT inhibitors; PRMT1 inhibitors; PRMT3 inhibitors; PRMT6 inhibitors; PRMT8 inhibitors; Protein arginine methyltransferase 1 inhibitors; Protein arginine methyltransferase 3 inhibitors; Protein arginine methyltransferase 6 inhibitors; Protein arginine methyltransferase 8 inhibitors
Latest Information Update: 14 Jul 2015
At a glance
- Originator Epizyme
- Developer Celgene International SARL; Epizyme
- Class Pyrazoles
- Mechanism of Action Histone methyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Leukaemia; Solid tumours